Comment on

• Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.

  Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. J Hepatol. 2013 Mar;58(3):495-501. doi: 10.1016/j.jhep.2012.10.017. Epub 2012 Oct 23. J Hepatol. 2013. PMID: 23099187
• Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?

  Toyoda H, Kumada T, Tada T. Toyoda H, et al. J Hepatol. 2013 Apr;58(4):838-9. doi: 10.1016/j.jhep.2012.11.034. Epub 2012 Dec 1. J Hepatol. 2013. PMID: 23207142 No abstract available.